The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2022
2023
2021
2020
2019
2018
2017
2016
2015
2013
All years
November 29, 2022
Interim report January – September 2022
November 24, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022
November 23, 2022
Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma
November 1, 2022
Promore Pharma provides an update on the Phase II clinical trial with ensereptide
August 30, 2022
Promore Pharma Interim report January – June 2022
August 23, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
August 10, 2022
Promore Pharma granted EU patent regarding treatment of chronic wounds
June 13, 2022
The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide
May 17, 2022
Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
May 17, 2022
Promore Pharma — interim report January-March 2022
May 13, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022
April 26, 2022
Promore Pharma’s Annual Report 2021 and AGM related Documents Published
April 12, 2022
NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)
March 17, 2022
Promore Pharma has reached recruitment goal in clinical trial of ensereptide
February 16, 2022
Interim report January – December 2021
February 16, 2022
First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan
February 9, 2022
Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021
January 31, 2022
Promore Pharma deregisters warrants
